PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
I-Mab Begins Study of Uliledlimab Plus Tecentriq in Advanced Solid Tumors
The firm will evaluate the combination's efficacy and potential biomarkers of response in patients with ovarian cancer, head and neck cancer, NSCLC, TNBC, and other cancers.
NeoImmuneTech Starts Phase II Trial of NT-17, Tecentriq in PD-L1-Positive NSCLC
The 83-patient study will evaluate the objective responses to the NT-17-Tecentriq combination, as well as progression-free and overall survival.
Agilent Gets CE Mark for Expanded Use of PD-L1 CDx in Triple-Negative Breast Cancer
The CDx, developed by Agilent and Merck, can now be used as an aid in identifying triple-negative breast cancer patients for treatment with pembrolizumab in the European Union.
Daiichi Sankyo, AstraZeneca, Merck Partner on Phase III Trial of TROP2, PD-1 Inhibitor Combo
The randomized, global trial will build on promising early data on the datopotamab deruxtecan-Keytruda combination from a Phase Ib study.
European Commission Approves Merck's Keytruda-Chemo Combination for Advanced TNBC Patients
The approval makes Merck's PD-1 inhibitor available to European TNBC patients whose tumors express PD-L1 with a combined positive score of at least 10.